Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

CTI and ROTE targets, UNITE update

Westpac Banking Corp
3:27pm
April 1, 2025
WBC’s new CEO hosted a market update which, amongst other things, provided FY29 CTI and ROTE targets, discussed the UNITE technology simplification program, and gave business unit updates. We’ve made forecast upgrades and lifted our 12 month target price to $29.02. WBC remains our preferred major bank, albeit potential TSR at current prices is -3%. Next key event is the 1H25 result due 5 May.

The Pursuit of Ravensthorpe

Medallion Metals
3:27pm
March 31, 2025
MM8 continues to progress the Ravensthorpe Gold Project (RGP) from concept to reality. The company has received multiple funding and offtake proposals from various counterparties, including project financing offers of up to A$50m, permitting efforts remain underway. Exclusive negotiations with ASX-listed IGO Ltd for the acquisition of the Forrestania processing infrastructure are advancing, with binding documentation well progressed. MM8 anticipates completion of negotiations within the 12-month exclusivity period. We reiterate our SPECULATIVE BUY rating, increasing our target price to A$0.41ps (from A$0.32ps).

Right Time, Right Place, Right Commodity

Meeka Metals
3:27pm
March 31, 2025
Development of the Murchison Gold Project (MGP) is tracking well to schedule with first gold due mid-2025. Expansions work on the process plant are progressing to schedule. Key infrastructure of the larger 750kW ball mill, cyclone cluster and structures have been installed. Open pit mining has commenced ahead of schedule with mining rates ramping up well, achieving ~20kBCM (Bank Cubic Meter) per pay, first ore is expected in April. We reiterate our SPECULATIVE BUY rating, increasing our target price to A$0.25ps (previously A$0.23ps) a function of increased spot gold prices.

Remaining hope fades as second Phase 3 fails

Opthea
3:27pm
March 31, 2025
After disappointing results in the Phase 3 COAST trial, showing lead drug candidate sozinibercept combined with standard of care (SOC) Eylea failed to show an improvement in mean change in best correct visual acuity (BCVA) at 52 weeks, the primary endpoint, the company opted to accelerate the readout of its other Phase 3 trial (ShORe), comparing sozinibercept with SOC Lucentis over the same timeframe and with the same primary endpoint. Like COAST, the ShORe trial failed to demonstrate any statistical difference in BCVA when comparing sozinibercept combination therapy with SOC. Management continues to access its obligations under a 2002 inked development funding agreement (DFA), where the company may be required to pay amounts that could material impact its solvency.

27 months to get back on track…a challenging goal

Healius
3:27pm
March 31, 2025
The investor day provided an update on the Lumus sale (closes 1 May-25; cA$300m special dividend (41.3c/sh fully franked)), a brief trading update (volumes +4%, revenue +6.2%), and importantly, the go forward strategy, which aims for operating leverage in the high single digit range by the end of FY27. Management’s ‘T27 plan’ aspires to grow revenue and lower the cost base via improved workforce planning and digital enablement across customer service, lab modernisation and emerging diagnostics. While management is confident the right ingredients are in place to succeed, with only 30% of flagged milestones completed to date, and an estimated A$110m+ in cost savings/efficiencies (>10% of the cost base) required to deliver on the goal, we view it as challenging. We adjust FY25-27 estimates with our target price falling to $1.32 from $1.35. Hold.

A great buy

The Reject Shop
3:27pm
March 27, 2025
TRS has entered into a scheme implementation agreement with Dollarama (DOL-TSX) to acquire all shares for $6.68 per share, which is a 112% premium to the previous closing price. This values TRS equity at A$259m. We think this is a strong offer which represents 95% upside to our previously published target price of $3.50. We move our price target to align with the TRS scheme offer price of $6.68 per share. Given the share price is now trading in line with the offer price, we retain a HOLD recommendation.

Strong heartbeat

EBR Systems
3:27pm
March 27, 2025
CY25 results were in line with expectations, with adequate funding for more than six quarters at the current burn. We see little risk to FDA approval for the company’s wireless cardiac pacing device (WiSE) on or before 13 Apr-25, with 2H25 launch. We view commercial and manufacturing readiness, along with a reimbursement path that is both streamlined and incentivised, as helping to smooth the transition from developmental stage into a commercially viable medical device business. We make nominal changes to CY25-26 forecasts, but raise our DCF-based valuation to A$2.86 (from A$1.76) on increased probability of FDA approval. Speculative Buy maintained.

Simplifying the business

Catalyst Metals
3:27pm
March 26, 2025
CYL has agreed to sell the non-core Henty Gold Mine to Kaiser Reef (ASX.KAU) for an upfront consideration of A$33m. The agreement lowers group unit costs and grants CYL the option to acquire 50% of the 250ktpa Maldon processing plant in Victoria. Drilling at Trident continues to validate the belt-scale growth proposition at Plutonic, mineralisation has been intersected 430m along strike and 600m below the existing resource indicating potential for material mine life extension. We upgrade our recommendation to ADD and our price target moves to A$5.69ps (previously A$4.56ps).

International Spotlight

Tesla
3:27pm
March 25, 2025
Tesla designs, develops, manufactures and sells fully electric vehicles; energy generation and storage systems; and offers related services around these products. The group operates under two reportable segments: (1) Automotive; and (2) Energy generation and storage. Within Automotive, Tesla manufactures five consumer vehicles and in 2022 began early production and deliveries of a commercial electric vehicle, the Tesla Semi. Tesla has product plans to launch a lower priced point vehicle and develop an autonomous Tesla ride-hailing network. Tesla continues to leverage developments in its proprietary Full Self-Driving (FSD) capability, battery cell and other technologies (namely robotics). The energy generation and storage segment includes the design, manufacture, installation, sales and leasing of solar energy generation and energy storage products. Tesla’s stated mission is to ‘accelerate the world’s transition to sustainable energy’.

International Spotlight

Siemens
3:27pm
March 25, 2025
Siemens AG is a technology company which engages in the areas of automation and digitalisation. It operates through the following segments: Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more